Titan Pharmaceuticals, Inc. TTNP

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company that develops proprietary therapeutics for the treatment of serious medical disorders.

Due Diligence starting point on Titan Pharmaceutical;

" Net income for the quarter ended March 31, 2013 was approximately $6.0 million, or approximately $0.08 per share, compared to a net loss of approximately $5.2 million, or approximately $0.09 per share, for the comparable period in 2012 . Net income in the quarter consisted of licensing revenue of approximately $3.8 million, resulting from the amortization of the non-refundable up-front license fee of $15.75 million (approximately $15.0 million, net of expenses) related to Titan’s licensing agreement with Braeburn for the exclusive U.S. and Canadian commercialization rights for Probuphine®, which was announced in December 2012. Probuphine is an investigational, long-acting, subdermal implant formulation of buprenorphine for the maintenance treatment of adult patients with opioid dependence."
http://www.titanpharm.com/press/2013/13-5-15-...ancial.htm

Company Website: http://www.titanpharm.com/

Company Financials: http://www.titanpharm.com/financials.htm